Connect your AI

Arcus Biosciences RCUS Increase (Decrease) in Contract with Customer, Asset

Increase (Decrease) in Contract with Customer, Asset at other companies

T-Mobile USTMUS

$61M-23.8%

Rocket Lab USA, Inc.RKLB

$13.43M+721%

Northrop GrummanNOC

$551M-48.5%

Bloom EnergyBE

$64.69M+4,292%

Ionis PharmaceuticalsIONS

$7.63M+115%

GE HealthCare TechnologiesGEHC

$46M+188%

Other financials

Income statement

Revenue$17.0M-39.3%

Operating income-$134.0M-9.8%

Net income-$128.0M-14.3%

EPS (diluted)-$1.02+10.5%

Balance sheet

Cash & equivalents$201.0M+4.7%

Total debt$113.0M+88.3%

Total equity$524.0M-1.3%

Total assets$997.0M-13.8%

Cash flow

Operating cash flow-$138.0M-4.5%

CapEx--100%

Free cash flow-$138.0M-3.8%

Valuation

Market cap$3.62B+226%

Enterprise value$3.53B+275%

P/S15.4×+7.5×

Profitability

Operating margin-168.6%-52.7pp

Net margin-156.4%-47.5pp

FCF margin-207.2%—

Returns & leverage

Return on equity-70%+8.4pp

Debt / equity0.2×+0.1×

Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerAsset.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's increase (decrease) in contract with customer, asset.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Arcus Biosciences's increase (decrease) in contract with customer, asset?: Arcus Biosciences (RCUS) reported increase (decrease) in contract with customer, asset of -$8M in Q1 2026.
How has Arcus Biosciences's increase (decrease) in contract with customer, asset changed year-over-year?: Arcus Biosciences's increase (decrease) in contract with customer, asset decreased by 60.0% year-over-year, from -$5M to -$8M.